Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
1993-8-31
|
pubmed:abstractText |
Fifteen cases with cutaneous reactions to calcium channel blockers (Ca-antagonist), dihydropiridine (including nicardipine, nifedipine, nisoldipine), verapamil, and diltiazem are reported. The patients from Yokohama City University Hospital and affiliated hospitals included 4 males and 11 females with cardiovascular diseases. Their average age was 64.7 (54 to 82) years. They had been taking Ca-antagonists for an average of 95 days (7 days to 10 years) before they developed dermatitis. The frequency of reactions to Ca-antagonists was high with diltiazem (5/16:31.25%) and dihydropyridine (7/16:43.75%), including nifedipine (4/7), nisoldipine (1/7), and nicardipine (2/7). Stevens-Johnson syndrome (MCOS) was associated only with verapamil. A notable type of eruption was the psoriasiform type, including exacerbation of psoriasis, which was resolved or easily controlled after discontinuation of the drug. Provocation tests verified the Ca-antagonist as the cause in 7 cases of psoriasiform eruption. The frequency of positive patch tests to Ca-antagonists was low except for diltiazem. Patch tests with diltiazem showed positive reactions in 54% (7 of 13 patients), based on our experience and papers published in Japan. Ca-antagonists are occasional causes of a wide spectrum of cutaneous reactions and should also be considered as causative factors in patients who develop psoriasiform eruptions or in patients whose psoriasis is exacerbated while using these drugs.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0385-2407
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
20
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
279-86
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:8340532-Aged,
pubmed-meshheading:8340532-Calcium Channel Blockers,
pubmed-meshheading:8340532-Drug Eruptions,
pubmed-meshheading:8340532-Erythema Multiforme,
pubmed-meshheading:8340532-Female,
pubmed-meshheading:8340532-Humans,
pubmed-meshheading:8340532-Male,
pubmed-meshheading:8340532-Middle Aged,
pubmed-meshheading:8340532-Psoriasis,
pubmed-meshheading:8340532-Skin
|
pubmed:year |
1993
|
pubmed:articleTitle |
Cutaneous reactions induced by calcium channel blocker: high frequency of psoriasiform eruptions.
|
pubmed:affiliation |
Department of Dermatology, Yokohama City University, Urafune Hospital, Japan.
|
pubmed:publicationType |
Journal Article,
Case Reports
|